BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 4, 2006
View Archived Issues
Veronate Data Crush Inhibitex; Drug's Future Cast Into Doubt
Shares in Inhibitex Inc. plunged by two-thirds Monday after the company released poor Phase III data on Veronate. (BioWorld Today)
Read More
Sirna, GSK Enter Respiratory Deal Worth Up To $700M-Plus
Read More
Cancer Drug Developers Running Out Of Excuses
Read More
FDA Holds Up Cortex's CX717; Incyte Scratching DFC For HIV
Read More
EPIX Buying Predix For $90M, With $35M Milestone Potential
Read More
Merrimack's Series E: $65M For Autoimmune, Oncology
Read More
Other News To Note
Read More
Appointments And Advancements
Read More
Clinic Roundup
Read More